These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 31227381)

  • 41. The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis.
    Paul M; Nielsen AD; Gafter-Gvili A; Tacconelli E; Andreassen S; Almanasreh N; Goldberg E; Cauda R; Frank U; Leibovici L
    Eur Respir J; 2007 Sep; 30(3):525-31. PubMed ID: 17537772
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of guideline-concordant antibiotics and macrolide/β-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study.
    Asadi L; Eurich DT; Gamble JM; Minhas-Sandhu JK; Marrie TJ; Majumdar SR
    Clin Microbiol Infect; 2013 Mar; 19(3):257-64. PubMed ID: 22404691
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia.
    Tessmer A; Welte T; Martus P; Schnoor M; Marre R; Suttorp N
    J Antimicrob Chemother; 2009 May; 63(5):1025-33. PubMed ID: 19293196
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial.
    Ceccato A; Cilloniz C; Ranzani OT; Menendez R; Agusti C; Gabarrus A; Ferrer M; Sibila O; Niederman MS; Torres A
    PLoS One; 2017; 12(6):e0178022. PubMed ID: 28617807
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial.
    Samsa GP; Matchar DB; Harnett J; Wilson J
    Chest; 2005 Nov; 128(5):3246-54. PubMed ID: 16304269
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative Efficacy of Beta-Lactams and Macrolides in the Treatment of Pediatric Pneumonia: A Systematic Review.
    Al Saeedy D; Gillani SW; Al-Salloum J; Moosvi A; Eissa M; Gulam SM
    Curr Pediatr Rev; 2020; 16(4):307-313. PubMed ID: 32895041
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Beta-Lactam Plus Macrolide for Patients Hospitalized With Community-Acquired Pneumonia: Difference Between Autumn and Spring.
    Kim Y; Jeon Y; Kwon KT; Bae S; Hwang S; Chang HH; Kim SW; Lee WK; Yang KH; Shin JH; Shim EK
    J Korean Med Sci; 2022 Nov; 37(45):e324. PubMed ID: 36413797
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The dilemma of monotherapy or combination therapy in community-acquired pneumonia.
    Vardakas KZ; Trigkidis KK; Apiranthiti KN; Falagas ME
    Eur J Clin Invest; 2017 Dec; 47(12):. PubMed ID: 29027205
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Beta-lactam versus beta- lactam/macrolide therapy in pediatric outpatient pneumonia.
    Ambroggio L; Test M; Metlay JP; Graf TR; Blosky MA; Macaluso M; Shah SS
    Pediatr Pulmonol; 2016 May; 51(5):541-8. PubMed ID: 26367389
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of antibiotic therapy in severe community-acquired pneumonia: Data from the Infauci study.
    Pereira JM; Gonçalves-Pereira J; Ribeiro O; Baptista JP; Froes F; Paiva JA
    J Crit Care; 2018 Feb; 43():183-189. PubMed ID: 28915392
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Comparison of the combination and quinolone therapy in community acquired pneumonia].
    Kılıç Soylar Ö; Kılınç O; Ellidokuz H
    Tuberk Toraks; 2015 Sep; 63(3):165-9. PubMed ID: 26523897
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization.
    Querol-Ribelles JM; Tenías JM; Querol-Borrás JM; Labrador T; Nieto A; González-Granda D; Martínez I
    Int J Antimicrob Agents; 2005 Jan; 25(1):75-83. PubMed ID: 15620830
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Experience with levofloxacin in a critical pathway for the treatment of community-acquired pneumonia.
    Marrie TJ
    Chemotherapy; 2004; 50 Suppl 1():11-5. PubMed ID: 15319549
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial.
    van Werkhoven CH; Postma DF; Mangen MJ; Oosterheert JJ; Bonten MJ;
    BMC Infect Dis; 2017 Jan; 17(1):52. PubMed ID: 28068956
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Doxycycline vs. macrolides in combination therapy for treatment of community-acquired pneumonia.
    Teh B; Grayson ML; Johnson PD; Charles PG
    Clin Microbiol Infect; 2012 Apr; 18(4):E71-3. PubMed ID: 22284533
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is gentamicin safe and effective for severe community-acquired pneumonia? An 8-year retrospective cohort study.
    Brereton CJ; Lennon D; Browning S; Dunn E; Ferguson JK; Davis JS
    Int J Antimicrob Agents; 2018 Jun; 51(6):862-866. PubMed ID: 29410326
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative antibiotic failure rates in the treatment of community-acquired pneumonia: Results from a claims analysis.
    Hess G; Hill JW; Raut MK; Fisher AC; Mody S; Schein JR; Chen CC
    Adv Ther; 2010 Oct; 27(10):743-55. PubMed ID: 20799007
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization.
    Peyrani P; Wiemken TL; Metersky ML; Arnold FW; Mattingly WA; Feldman C; Cavallazzi R; Fernandez-Botran R; Bordon J; Ramirez JA
    Infect Dis (Lond); 2018 Jan; 50(1):13-20. PubMed ID: 28699429
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? An individualised approach supported by machine learning.
    König R; Cao X; Oswald M; Forstner C; Rohde G; Rupp J; Witzenrath M; Welte T; Kolditz M; Pletz M;
    Eur Respir J; 2019 Dec; 54(6):. PubMed ID: 31537702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.